Introduction
Information transfer in the nervous system occurs through generation of action potentials in neurons and synaptic potentials at synaptic junctions. It is known that the magnitude of the potentials generated at the synapses can be modified by their prior activity expressing phenomenon of synaptic plasticity. The best-known examples of synaptic plasticity considered to be the basis of learning are longterm potentiation (LTP)
1,2 and long-term depression (LTD). 3 While postsynaptic activation contributes to the generation of evoked potentials, it has to be preceded by the action potential generated at the axon hillock. Although the action potential has been always considered as a steady signal, resistant to any stimulation-dependent modifications, some recently published results, [4] [5] [6] including the data from our Keywords ► compound action potential ► glutamate ► axonal plasticity
Abstract
Background Our previous experiments demonstrated modulation of the amplitude of the axonal compound action potential (CAP) by electrical stimulation. To verify assumption that glutamate released from axons could be involved in this phenomenon, the modification of the axonal CAP induced by glutamate was investigated. Objectives The major objective of this research is to verify the hypothesis that axonal activity would trigger the release of glutamate, which in turn would interact with specific axonal receptors modifying the amplitude of the action potential. Methods Segments of the sciatic nerve were exposed to exogenous glutamate in vitro, and CAP was recorded before and after glutamate application. In some experiments, the release of radioactive glutamate analog from the sciatic nerve exposed to exogenous glutamate was also evaluated. Results The glutamate-induced increase in CAP was blocked by different glutamate receptor antagonists. The effect of glutamate was not observed in Ca-free medium, and was blocked by antagonists of calcium channels. Exogenous glutamate, applied to the segments of sciatic nerve, induced the release of radioactive glutamate analog, demonstrating glutamate-induced glutamate release. Immunohistochemical examination revealed that axolemma contains components necessary for glutamatergic neurotransmission. Conclusion The proteins of the axonal membrane can under the influence of electrical stimulation or exogenous glutamate change membrane permeability and ionic conductance, leading to a change in the amplitude of CAP. We suggest that increased axonal activity leads to the release of glutamate that results in changes in the amplitude of CAPs. laboratory, 7 indicate that the properties of the action potential may be modified by axonal activity induced by either electrical or magnetic stimulation. According to the classical definition, a neurotransmitter is a molecule which is released from presynaptic nerve terminals in response to stimulation and subsequently binds to postsynaptic or presynaptic receptors. However, this classical view has been challenged by several reports, 5, 6 indicating that axons can also release neurotransmitter-like substances in a Ca 2þ -dependent way without involvement of the synapses. [8] [9] [10] [11] Exposure of sciatic nerve segments to a specific pattern of magnetic 7, 12 or electrical 13 stimulation increased the amplitude of the evoked compound action potentials (CAPs) and simultaneously enhanced the release of glutamate. 7 As these nerve preparations contained neither synaptic connections nor cell bodies, the mechanism of the observed amplification had to be intrinsic to the axon.
Materials and Methods
Animals CD-1 mice of both sexes, 1 to 3 months old, kept in normal day light/dark cycle were used in all experiments. All procedures and number of the animals were approved by the Institutional Animal Care and Use Committee of the College of Staten Island/CUNY, and were in conformity with National Institutes of Health Guidelines
Preparation of Sciatic Nerve
The animals were sacrificed by cervical dislocation, both hind limbs were skinned, and sciatic nerves were dissected out. The nerves were cut into 7 to 10 mm segments and placed in oxygenated 
Electrophysiological Recordings
The extracellular CAP was recorded with iridium microelectrode (0.180-mm shaft diameter; 1-2-μm tip; 5.0 MΩ; WPI, Sarasota, Florida, United States) placed inside the epineurium at the end of the segment. A stainless steel bipolar stimulating electrode (500-μm shaft diameter; 100-μm tip; FHC, Maine, United States) was localized outside of epineurium. The distance between the stimulating and recording electrodes varied in different experiments (5-7 mm) and was adjusted to obtain good quality recording, with CAP clearly separated from the stimulus artifact. The nerves were stimulated in all experiments with the frequency of 0.03 Hz. LTP program 14 was used to generate the pulses which were applied during entire experiment. Different chemicals were added to the recording chamber following stabilization of the potential. The record of extracellular activity was passed through a standard head stage, amplified (Neuro Amp EX, ADInstruments, Inc, Colorado, United States) and stored for further analysis.
The Latency and the Area Measurements
The latency was measured as the time elapsing between the start of the stimulus and the beginning of the first negativity of the CAP. To measure the area, an imaginary line was drawn by the computer between the first positivity of the potential and the first point of the stable baseline after recording of CAP. This first point of baseline stability was automatically determined by the computer usually after recording of three to four CAPs (►Fig. 1A). Then the area contained by this imaginary line and the shape of the potential were measured on the hard copy of the recordings with planimeter, expressed in mm 2 hours continues to express evoked activity. At vial number 8, the exogenous glutamate has been injected into perfusion system. The amount of D-Asp was evaluated in all vials in the scintillation counter. The increase in the release of 3 H-D-Asp was expressed as the area under the peak of release divided by total area under the curve representing the release.
Immunohistochemistry
The nerves were fixed in 4% paraformaldehyde for 24 hours and subsequently placed in 30% sucrose solution for 24 hours. Then, 30-µm cryosections were prepared and transferred onto slides and washed with phosphate-buffered saline (0.01 M, pH 7.4) three times (10 minutes each), permeabilized, and blocked with 2% nonfat dry milk in phosphate buffer saline, containing 0.02% TritonX-100 and 10% normal goat serum for 1 hour. Next, the sections were incubated overnight (at 4°C) with the primary antibody after three washes with phosphate buffer saline. The in vitro expression of various channels and receptors was analyzed with the following antibodies (diluted in nonfat dry milk-phosphate buffer saline with 2% normal goat serum): rabbit anti-GluR 2/ 3 (1:500; Millipore Corp., Massachusetts, United States), mouse anti-EAAC1 (1:500; Chemicon International Inc., California, United States), mouse anti-nonfat dry milk R2B (1:500), rabbit anti-Ca (1:500), mouse anti-Na (1:500), and rabbit anti-AMPA (1:500). The following day, the samples were blocked for 1 hour with 10% normal goat serum in nonfat dry milk-phosphate buffer saline, and then washed and incubated for 1 hour at room temperature with secondary antibodies diluted in nonfat dry milk-phosphate buffer saline, with 2% normal goat serum. The dilution of the secondary antibodies were 1:250 Cy5 (Jackson ImmunoResearch laboratories, Inc., Pennsylvania, United States) (goat anti-mouse) and Alexa fluor 488 (1:250; Santa Cruz Biotechnology, Inc., California, United States) (goat anti-rabbit). The nuclei were counterstained and finally cover-slipped with Prolong Gold antifade reagent with 4',6-diamidine-2-' phenylindole dihydrochloride (DAPI, Invitrogen, Eugene, Oregon, United States). Images were captured using confocal microscopy (Leica SP2 AOBS) using a 488-nm Ar/Kr laser for the Alexa fluor 488,543-nm HeNe laser for Cy5 and 405-nm diode laser for DAPI. Images were reconstructed from Z stack using Leica software.
The Evaluation of Intracellular Calcium with Imaging Quantitative Measurements
Fluo3 (5 µM) was added to the nerve-containing dish for 30 minutes. To determine baseline [Ca 2þ ], three frames before the addition of the drugs were taken and the fluorescence intensity of these images was used as baseline. The changes in the fluorescent intensity in subsequent images after addition of the glutamate were expressed as percentage of the baseline. Confocal images of cellular fluorescence were obtained using a Leica inverted microscope (Leica SP2 AOBS) equipped with a dry 10Â HC PL fluotar 10Â 0.3 dry objectives. The excitation wavelength used was 496-nm Ar/Kr laser, and the emission wavelength of the ionophore for the intensity measurement was 509 to 596 nm. All recordings were performed at room temperature (22-25°C). Three base scans were recorded and then recording chamber was loaded with one of the following: glutamate (100 µM), N-methyl-D-aspartate (NMDA) (10 µM), or MK801 (50 µM), and the images were then taken every 30 seconds. The changes in free calcium concentration inside the axon were evaluated by comparison of the baseline fluorescent intensity with the intensity after addition of given molecule. Data were expressed as percent changes in fluorescent intensities.
Chemicals Used
Chemicals purchased from Sigma:NMDA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic; kainic acid; kynurenic acid; dizocilpine; 6-cyano-7-nitroquinoxaline-2, 3-dione. All other standard molecules are used to prepare standard solutions. Chemicals purchased from Tocris: DL-threo-β-benzyloxyaspartate; verapamil; sodium dantrolene. Chemical from Invitrogen: Fluo-3.
Statistics
All data were postanalyzed offline and statistics were computed in Statistica V 6.1 (Statsoft, Inc. Tulsa, Oklahoma, United States) and MatLab software. Data were analyzed with analysis of variance (ANOVA) and paired t-test unless specified otherwise. All data are expressed as mean AE SEM.
Results

The Modification of CAP Characteristics by Exogenous Glutamate
Following stabilization of CAP amplitude, glutamate (100 µM) was added to the recording chamber. As depicted in ►Fig. 1A, CAP amplitude started to increase approximately 10 minutes after addition of glutamate and gradually reached its maximum approximately 75 minutes after addition of glutamate. To standardize experimental conditions, all experiments were terminated 75 minutes after addition of glutamate. The amplitude of 10 potentials recorded at the end of the experiment was averaged and taken as an indicator of amplification. ►Fig. 1B illustrates mean CAP amplitude before (0.04 AE 0.01 mV) and after (0.53 AE 0.41 mV) addition of glutamate (p < 0.005, n ¼ 9, t-test). The increase in the amplitude of CAP was accompanied by decrease in CAP latency. As depicted in ►Fig. 2A, the mean latency was reduced from 3.91 ms recorded before glutamate addition to 3.74 ms observed at the end of the experiment (p < 0.00003, n ¼ 10, t-test). In parallel with increased amplitude and decreased latency, the area of CAP was significantly enhanced from 0.670 cm 2 before glutamate application to 0.682 cm 2 after glutamate addition (p < 0.002, n ¼ 12, ►Fig. 2B).
Inhibition of Glutamate-Induced CAP Amplification
Kynurenic acid, a general antagonist of glutamergic receptors, blocked glutamate-induced amplification, but it did not influence the amplitude of CAP by itself (►Fig. 3A, middle bar; CAP 0.08 AE 0.02 mV both before and after glutamate application, p ¼ 0.7, n ¼ 10). ►Fig. 3A (right bar) illustrates the averaged results of 10 experiments aimed to evaluate the effects of glutamate in the presence of kynurenic acid (mean before ¼ 0.07 AE 0.02 mV, mean after ¼ 0.06 AE 0.02 mV; p < 0.04, n ¼ 10). Thus, blocking glutamate receptors does not affect baseline axonal transmission. Selective antagonist of NMDA receptor, MK801, had no effect on CAP amplitude, but eliminated the effect of glutamate added later (►Fig. 3B, the middle and right bars, p ¼ 0.515, n ¼ 5). Similarly, CNQX (an antagonist of AMPA/ kainate receptors) prevented the effects of glutamate. As depicted in ►Fig. 3C, there is no statistical difference between the averaged amplitudes of CAP recorded in the presence of CNQX alone and in the presence of glutamate (p ¼ 0.745, n ¼ 7). A slight attenuation of CAP following addition of CNQX was not statistically significant.
The Influence of Glutamate Receptor Agonists on the Amplitude of CAP
The mixture of 10-µM NMDA and 10-µM kainate (agonists of glutamergic receptors) added to the recording chamber significantly increased CAP amplitude (►Fig. 4). The mean values of CAP amplitude before and after the addition of NMDA and kainate were 0.19 AE 0.059 and 0.258 AE 0.0662 mV, respectively (p < 0.005, n ¼ 8). These data support the view that glutamate mediates its actions on the CAP through activation of the AMPA/kainate and NMDA receptors. 
The Role of Calcium in Glutamate-Induced CAP Increase
The addition of glutamate in Ca 2þ -free Ringer's solution had no effect on CAP amplitude (►Fig. 5A). The mean values of CAP recorded before and after addition of glutamate were 0.083 AE 0.016 and 0.072 AE .0122 mV, respectively (p ¼ 0.060, n ¼ 8). In agreement with the results of these experiments, verapamil prevented glutamate-induced increase in CAP (►Fig. 5B; p ¼ 0.529, n ¼ 6). Since glutamate applied in the presence of dantrolene also had no influence on the amplitude of CAP (p ¼ 0.623, n ¼ 6, ►Fig. 5C), one can assume that the calcium released from endoplasmic reticulum may additionally participate in the action of exogenous glutamate. As in the case of verapamil, dantrolene itself had no effect on CAP (►Fig. 5C, middle bar). Moreover, the experiments with calcium channel antibody revealed that there are indeed voltage-sensitive calcium channels present on the surface of the sciatic nerve (►Fig. 5D).
Glutamate-Induced Release of Radioactive Glutamate Analog (2,3-3 H-D-Aspartate) from the Segments of Sciatic Nerve In Vitro
If exogenous glutamate exerts influence on the amplitude of the action potential, similar action could be expressed by endogenous glutamate released from axons during intense activity. This action of endogenous glutamate could be further amplified by the glutamate-induced glutamate release. To verify this assumption, we tested the effect of exogenous glutamate on the release of radioactive analog of glutamate 3 H-D-Asp from the segments of the sciatic nerve. As depicted 
Quantitative Measurements of Intracellular Calcium Using Calcium Imaging
As depicted in ►Fig. 7A, there was a significant increase in fluorescence intensity within 60 seconds following addition of glutamate (p < 0.05, n ¼ 3). The increase was transient, indicating the presence of buffering mechanism that quickly reduces the concentration of free axoplasmic calcium. Addition of NMDA, which activates channels permeable for both calcium and sodium, induced slowly developing increase in fluorescence which remained elevated for the rest of the experiment (p < 0.05, n ¼ 3, ►Fig. 7B).
As expected, MK801 completely blocked the NMDA-induced increase in axoplasmic free calcium. There was no increase in the fluorescence intensity neither after the addition of MK801 itself (►Fig. 7C, averaged results of three experiments) nor after the addition of NMDA and MK801 to the recording chamber (►Fig. 7D, averaged results of three experiments).
Immunohistochemical Characterization of Channel Expression on the Axolemma
The data presented thus far use pharmacological agents to provide functional evidence for the presence of various channels on the membrane of axons within the sciatic nerve. Therefore, we sought to use immunofluorescence to probe for the presence of channels and receptors to correlate morphological, pharmacological, and electrophysiological observations. As anticipated, the axons within the sciatic nerve express high level of voltage-sensitive sodium channels (►Fig. 8A). We have also determined that axonal membrane contains all the molecular components necessary for Fig. 8 The axonal expression of molecules essential for generation of the action potential and glutamatergic neurotransmission. (A) The sciatic nerve expresses high level of voltage-sensitive sodium channels (red); (B) The sciatic nerve expresses AMPA/kainate receptors (green) and excitatory amino acid transporter (red); (C) Sections from sciatic nerve immunostained with antibody against NMDA receptors (green) and mGluR (red); (D) the sections of sciatic nerve expressing NMDA receptor (red). All these images were obtained from sections from sciatic nerve of 1-to 3-month-old CD-1 mice immunostained with antibody against specific molecules. glutamatergic neurotransmission. ►Fig. 8 illustrates the distribution of immunoreactive particles for AMPA/kainate (►Fig. 8B), NMDA (►Fig. 8C, D), and mGlur2 (►Fig. 8C) receptors. We have also found ample immunoreactivity indicating the presence of amino acid transporters (►Fig. 8D).
Discussion
Although action potentials in peripheral nerves have been always considered as steady signals, resistant to any stimulation-dependent modifications, some recently published results, [4] [5] [6] including the data from our laboratory, 7, 13 indicate that the properties of the action potential may be modified by specific axonal activity. Moreover, it has been shown that sciatic nerve releases glutamate in response to repeated stimulation 7 and to exogenous glutamate. The results presented here strongly suggest that glutamate released during intense axonal activity would be responsible for the observed CAP amplification. In the currently described experiments, the exogenous glutamate would mimic the action of electrical stimulation. The addition of exogenous glutamate increased the amplitude of CAPs in sciatic nerve preparations. The glutamateinduced increase of the CAPs was calcium-dependent and could be abolished by glutamate receptors antagonists. Moreover, the segments of sciatic nerve preloaded with radioactive glutamate analog, D-Asp, released this analog in response to exposure to exogenous glutamate. The ability of the segments of axons in vitro to generate evoked action potentials validates our data and makes processes induced by exogenous glutamate very likely to occur in vivo. Immunohistochemical analysis revealed that axolemma of the peripheral nerves is equipped with several proteins important for neuronal communication mediated by glutamate. Apparently, these proteins can under the influence of electrical stimulation or exogenous glutamate change membrane permeability, leading to the changes in the amplitude of the CAPs. These changes demonstrate the existence of axonal plasticity expressed as an alteration in the amplitude of the action potential following periods of variable activity accompanied by axonal release of glutamate.
7 This glutamate, through paracrine action, can in turn affect adjacent axons, inducing long-lasting modifications in the properties of the nerve. The axonal plasticity would constitute exclusive property of the axon and could contribute together with different forms of synaptic plasticity 1,3 to use-dependent modifications of the activity of neuronal networks. It is not known exactly what would be extracellular concentration of glutamate during repetitive axonal stimulation, although it is known that it can reach higher micromolar levels during synaptic activity in the central nervous system. 15 We have selected 100-µM concentration of exogenous glutamate for electrophysiological experiments considering the fact that this exogenous glutamate would have to penetrate through epineurium, perineurium, and endoneurium to reach glutamate receptors located on the neuronal and glial cells membranes. 16 It has to be emphasized that exogenous glutamate injected to the perfusion system was quickly diluted approximately 20-fold before it reached the preparation of the sciatic nerve in the perfusion chamber. Therefore, ►Fig. 6B shows the effective concentrations of exogenous glutamate in the vicinity of sciatic nerve within the range of 25 to 1,000 µM. The transient increase in the extracellular glutamate concentration, occurring due to either repetitive axonal activity or application of exogenous glutamate, would result in temporary elevation of intra-axonal free calcium concentration originating from extracellular and intracellular sources following the opening of different channels. The action of these calcium channels has to be synchronized to induce amplification of CAP. Therefore, one can assume that the intra-axonal increase in calcium concentration has to be compartmentalized. It would correspond to individual calcium channels localized in the proximity of other signaling molecules (e.g., glutamate receptors, Ca 2þ channels, nitric oxide synthase), organized along the internodal axolemma under the myelin sheath in discrete "axonal nanocomplexes." Although overactivation of nanocomplexes during disease can lead to a lethal release of Ca 2þ from intra-axonal stores, 17,18 the discreet interaction of exogenous glutamate with these nanocomplexes and subsequent controlled elevation of intracellular calcium concentration could explain the increase in CAP in our experiments. The role of NMDA receptors, which seem to be crucial for axonal plasticity, supports our assumption. found that 100-µM glutamate and 100-µM NMDA increased the CAP recorded from dorsal column axons of neonatal rats.
As demonstrated by Nikolaeva et al, 21 the release of calcium from intra-axonal stores is highly dependent on Na þ influx and reversal of the mitochondrial Na þ /Ca 2þ exchanger. 21 Although this observation suggests that both of these pathways contribute to the intra-axonal calcium concentration and work independently, 21 mitochondrial calcium is not likely to be involved in CAP increase observed in our experiments. Dantrolene, which blocks IP3 receptor-linked intracellular calcium channels, completely eliminated the increase of CAP. Therefore, we would like to suggest that influx of calcium via NMDA receptors-linked channels initiates calcium release from internal, ryanodine receptor-regulated channels by the mechanism described for cardiac muscle.
22
The reduced latency and increased area of CAP after glutamate application could be explained in view of the results reported by Sasaki et al. 23 They have determined that individual action potentials recorded from hippocampal single axons increased their duration following application of exogenous glutamate. The glutamate-induced axonal plasticity may, as a consequence of axonal repeated activation, represent beneficiary effect exerted in neuromuscular system by extensive physical activity. Indeed, the presence of several ions channels, carriers, and receptors visualized in axonal membranes by us apparently creates environment permissible for modification of the action potential during its propagation down the axonal length. Our novel data together with published results clearly indicate that in spite of prevailing notion about "all-ornothing" property of the action potential, axons and action potentials are capable of conveying the information in an analog manner. 24 
Conclusion
Repetitive generation of the action potentials in the peripheral nerve would result in nonsynaptic, glial, and/or axonal release of glutamate. This release could occur at activated nanocomplexes, which would mimic the synaptic action, releasing glutamate. Released glutamate would further enhance its action by glutamate-induced glutamate release. The transient increase in extracellular glutamate would in turn activate calcium-dependent processes, which would result in an increase in the amplitude of CAP. This phenomenon, representing axonal plasticity, could explain beneficial effects of repetitive muscle activation on the recovery from the injury.
